EGFR and cancer: Therefore, percentages of patients with genetic alterations in EGFR (7%), FGFR (6%), mTOR (4%), and iNOS (3%) as reported in this study were on the high side and thus strengthen our earlier observations that these signatures are very important in cancer progression and can thus serve as attractive targets worthy of further exploration.